Cogent Biosciences Inc Stock Price, News & Analysis

Cogent Biosciences (NASDAQ: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 5, 2025, at 7:35 a.m. ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days.

Additionally, the company disclosed the approval of inducement equity awards for five new employees under its 2020 Inducement Plan. The awards consist of options to purchase 127,000 shares of Cogent common stock, featuring a 10-year term and a four-year vesting schedule.

Cogent Biosciences (Nasdaq: COGT) presented preclinical data from four pipeline programs at the AACR 2025 Annual Meeting in Chicago. The presentations included: a pan KRAS(ON) inhibitor showing 90% tumor growth inhibition; CGT6297, a PI3Kα inhibitor targeting H1047R and helical mutations; CGT4859, a selective FGFR2/3 inhibitor currently in Phase 1 trials; and CGT4255, a brain-penetrant ErbB2 inhibitor.

The company also announced two key leadership appointments: Ray Frost as SVP of Market Access and Dr. Adam Boyd as SVP of Corporate Strategy. Additionally, Cogent granted inducement equity awards to five new employees, including nonqualified options to purchase 446,000 shares with a 4-year vesting schedule.

Cogent Biosciences (NASDAQ: COGT) announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations showcase the company's advancement in precision therapies:

• A potent KRAS (ON) inhibitor with selective mutation targeting
• CGT6297: A novel PI3Kα H1047R mutant-selective inhibitor
• CGT4859: A reversible and selective FGFR2/3 inhibitor addressing resistance mutations
• CGT4255: An EGFR sparing, pan-mutant HER2 candidate with potential brain penetration capabilities

Additionally, the company granted an inducement equity award to a new employee, consisting of options to purchase 9,700 shares with a 4-year vesting schedule, approved under Nasdaq Listing Rule 5635(c)(4).

Cogent Biosciences (Nasdaq: COGT) has announced its upcoming participation in a fireside chat at the Leerink Healthcare Conference scheduled for March 12, 2025, at 10:00 a.m. ET. The event will be accessible via webcast on the company's Investors & Media webpage, with replay available for 30 days.

Additionally, the company disclosed an inducement equity grant approved by its Compensation Committee on March 4, 2025. Under Nasdaq Listing Rule 5635(c)(4), a new employee received options to purchase 90,000 shares of Cogent common stock. The option features a 10-year term, with a 4-year vesting schedule: 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.

Cogent Biosciences (NASDAQ: COGT) has reported expanded clinical results from the Open Label Extension (OLE) portion of SUMMIT trial, evaluating bezuclastinib in nonadvanced systemic mastocytosis patients. The data, presented at AAAAI/WAO 2025, showed remarkable improvements after 48 weeks of treatment:

Key findings include:

• 65% mean improvement in Total Symptom Score (TSS)
• 88% of patients achieved >50% TSS reduction
• 94% of patients exceeded 30% TSS reduction
• 63% reduction in most severe symptoms

The trial involved patients with median age 52 years (range 36-76). Safety data from August 2024 showed mostly low-grade, reversible adverse events, primarily hair discoloration and transaminase elevations. The median treatment duration was 56 weeks for the active arm and 40 weeks for placebo crossover patients. Top-line results from SUMMIT Part 2 registration-directed trial are expected in July 2025.

Cogent Biosciences (NASDAQ: COGT) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical trials for bezuclastinib. The company expects top-line results from three pivotal trials in 2025: SUMMIT trial (NonAdvSM) in July, APEX trial (AdvSM) in 2H, and PEAK trial (GIST) by year-end.

Clinical highlights include impressive data from the SUMMIT trial showing 56% mean improvement in Total Symptom Score and 89% of patients with >50% decrease in serum tryptase levels. The APEX trial demonstrated 52% overall response rate per mIWG criteria, rising to 83% for patients receiving 100mg BID.

Cogent's pipeline expansion includes a selective KRAS inhibitor (CGT6737) and PI3Kα inhibitor (CGT6297). The company plans to submit IND applications in 2025 for CGT4255 (ErbB2 inhibitor) and CGT6297.

Financially, Cogent reported $287.1 million in cash and equivalents as of December 31, 2024, plus $25 million from an ATM offering in February 2025. This funding is expected to sustain operations into late 2026, well past planned clinical readouts. R&D expenses increased to $232.7 million for 2024, up from $173.8 million in 2023, while net loss widened to $255.9 million from $192.4 million.

Cogent Biosciences (Nasdaq: COGT) has announced an upcoming poster presentation featuring bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in San Diego. The presentation will focus on a subgroup of patients who received 100mg bezuclastinib for at least 48 weeks in the ongoing Summit Trial, highlighting long-term symptomatic benefits.

The poster, titled 'Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib,' will be presented on March 1, 2025, from 9:45-10:45am PT at the San Diego Convention Center.

Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Wednesday, February 5, 2025 at 9:30 a.m. ET in New York.

Interested parties can access a live webcast of the presentation through the Investors & Media section of Cogent's website. The presentation recording will be made available approximately two hours after the event and will remain accessible for 30 days on the company's investor relations platform.